Exhibit 1 Joint Filing Agreement This will confirm the agreement as of February 8, 2005 by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial...Joint Filing Agreement • February 14th, 2005 • MDS Capital Corp • Laboratory analytical instruments
This will confirm the agreement as of February 8, 2005 by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial ownership by the undersigned of the shares of the common stock, $.001 par value per share, of Immunicon Corporation, a Delaware corporation, is being filed on behalf of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.
Exhibit 1 Joint Filing Agreement This will confirm the agreement as of February 8, 2005 by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial...Joint Filing Agreement • February 14th, 2005 • MDS Capital Corp • Pharmaceutical preparations
JOINT FILING AGREEMENTJoint Filing Agreement • February 21st, 2014 • LCC Legacy Holdings Inc. • Pharmaceutical preparations
In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, par value $0.001, of Argos Therapeutics Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.
Joint Filing AgreementJoint Filing Agreement • February 3rd, 2009 • Lumira Capital Corp • Orthopedic, prosthetic & surgical appliances & supplies
This will confirm the agreement as of February 3, 2009, by and among all the undersigned that the Statement on Schedule 13G filed on or about this date and any further amendments thereto with respect to beneficial ownership by the undersigned of the shares of the common stock, $0.001 par value per share, of MAKO Surgical Corp, a Delaware corporation, is being filed on behalf of each of each of the undersigned in accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934.
AGREEMENTSchedule 13g Agreement • February 14th, 2008 • Lumira Capital Corp • Pharmaceutical preparations
Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Pharmasset, Inc.
